Foundation Medicine will acquire SAGA Diagnostics’ Pathlight MRD platform, expanding its cancer monitoring portfolio. The $595 million deal is expected to close by Q3 2026, with integration supporting treatment selection and recurrence monitoring.
The Idylla CDx MSI Test detects microsatellite instability in colorectal cancer tissue in under three hours, supporting therapy selection for eligible patients.
A peer-reviewed study suggests molecular signatures can be identified without invasive uterine sampling using whole-transcriptome sequencing and machine learning.
Cirena has licensed a University of Colorado Boulder RNA synthesis technology, enabling scalable production of high-purity, 100–400 nt RNA constructs for CRISPR, functional genomics, and RNA therapeutics research.
Read More
Baylor Genetics has added optical genome mapping and long-read sequencing to its whole genome sequencing test, expanding STR analysis, enabling FMR1 methylation detection, and improving structural variant interpretation.
Read More
The FDA has granted Breakthrough Device Designation to MeMed BV Flex, an AI-powered capillary blood test designed to distinguish bacterial from viral infections in 15 minutes using host-response biomarkers.
Read More
The Menlo Park-based company is integrating epigenetic signatures into its rare disease diagnostics offering, with the new capability set to roll out automatically in early Q2 2026.
Read More
The Phase 2 grant supports AI-driven analysis of retinal tissue to identify disease-specific patterns linked to ALS, FTD, and LATE.
Read More
Swiss company’s 1536-well technology aims to make transcriptomics cost-effective for primary drug screening and toxicology applications.
Read More
Johns Hopkins researchers have developed an AI-driven liquid biopsy that uses cell-free DNA fragmentation patterns to detect early liver fibrosis and cirrhosis, according to a study in Science Translational Medicine.
Read More
Research demonstrates an automated next-generation sequencing workflow designed to reduce hands-on time while delivering next-day CGP results.
Read More
Illumina has announced an 18-month roadmap for NovaSeq X, featuring a 40% output increase to 35 billion reads, faster turnaround times, new flow cell options, and the introduction of Q70 quality scores.
Read More
The integrated testing approach combines genomic profiling with immunohistochemistry to support faster treatment decisions for advanced-stage cancer patients.
Read More
Tumor-informed blood test uses whole-exome sequencing and bioinformatics to identify trace tumor DNA before recurrence appears on imaging.
Read More
The Galleri blood test demonstrated a four-fold increase in cancer detection rates and substantial reduction in stage IV cancer diagnoses in 142,000 participants.
Read More
The mcPCR platform enables copying of DNA methylation patterns during amplification, addressing a key limitation in current PCR methods for disease detection.
Read More
The new platform delivers twice the throughput in half the footprint of the previous generation, targeting large-scale genomic applications.
Read More
High-resolution maps showed us where cells live; the next phase of spatial omics is about extracting those cells and uncovering the molecular conversations that shape outcomes.
Read More